What we do
MarketVIEW: RSV vaccines (Apr '14)
MarketVIEW: Rabies vaccines (Mar '14)
MarketVIEW: Zoster vaccines (Jan '14)
MarketVIEW: Quadrivalent influenza vaccines (Jan '14)
MarketVIEW: Clostridium difficile vaccines (Dec '13)
MarketVIEW: Inactivated polio virus vaccines (Nov '13)
MarketVIEW: Chagas disease vaccines (Nov '13)
MarketVIEW: Cocaine dependence vaccines (July '13)
MarketVIEW: Ross River virus vaccines (July '13)
MarketVIEW: Diabetes vaccines (June '13)
MarketVIEW: Yellow fever vaccines (June '13)
MarketVIEW: Cholesterol vaccines (Mar '13)
MarketVIEW: Smoking cessation vaccines (Mar '13)
MarketVIEW: Hepatitis E virus vaccines (Feb '13)
MarketVIEW: Hepatitis C virus vaccines (Feb '13)
MarketVIEW: Alzheimer's disease vaccines (Jan '13)
MarketVIEW: Hepatitis B virus vaccines (Jan '13)
MarketVIEW: West Nile vaccines (Dec '12)
MarketVIEW: Acne vaccines (Sept '12)
MarketVIEW: Candida vaccines (July '12)
MarketVIEW: HSV TX vaccines (July '12)
MarketVIEW: HAV (Emerging) vaccines (July '12)
MarketVIEW: Quadrivalent influenza vaccines (June '12)
MarketVIEW: S.aureus (Apr '12)
MarketVIEW: Enterovirus-71 (Feb '12)
MarketVIEW: Clostridium difficile (Feb '12)
MarketVIEW: meningococcus serogroup B (Jan '12)
MarketVIEW: universal pneumo (Jan '12)
MarketVIEW: Travelers' diarrhea (Oct '11)
MarketVIEW: JE vaccines (Jan '12)
MarketVIEW: GAS vaccines (June '11)
MarketVIEW: Melanoma vaccines (June '11)
MarketVIEW: Dengue vaccines (Jan '12)
EpibaseID: Global epidemiology database (Oct '11)
MarketVIEW: Lyme Borreliosis vaccines (Nov '10)
VacZine Analytics is an established strategic research consultancy based in the United Kingdom.
We provide high-quality disease and commercial analysis to those working within or in collaboration with the vaccine industry.
Our key focus is helping clients build the case for developing new vaccines
Group B Streptococcus
54th ICAAC, Washington DC conference - selective innovation won't do!
Pfizer vaccines boosts presence with low risk Baxter acquisitions.
Caribbean Chikungunya outbreak should move vaccine back onto the agenda.
Novartis to the vaccines industry - can we have our money back please?
BexseroŽ: good for UK children, Novartis Vaccines and a flat industry.
H7N9, like H5N1 - re-exposes weaknesses in pandemic vaccine development
2013 FY results - QIVs: a highlight in a flat industry.
Clostridium difficile vaccines: multipronged US-biased strategy to reduce economic burden.
Meningococcal group B vaccine, BexseroŽ: too late for the science? Stick to the wider economics.
Tweets by @VacZineAnalytic
© 2013 VacZine Analytics. All rights reserved.
Terms and conditions
We sponsor Group B Strep Support.